Acute respiratory distress syndrome

BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections

Retrieved on: 
Wednesday, February 7, 2024
IL-8, COVID-19, Inflammation, Cytokine, Urinary tract infection, Downregulation and upregulation, MD, Therapy, Patient, University, Lung, Rhinovirus, Acute respiratory distress syndrome, Protein, RSV, Infection, Neutrophil, Blood, AXL, IL-6, Viral

The data presented by Dr. Spalluto showed bemcentinib had activity in human in vitro models of infection caused by Respiratory Syncytial Virus (RSV), influenza and rhinovirus.

Key Points: 
  • The data presented by Dr. Spalluto showed bemcentinib had activity in human in vitro models of infection caused by Respiratory Syncytial Virus (RSV), influenza and rhinovirus.
  • In these models, bemcentinib downregulated IL-6 and IL-8, two important inflammatory cytokines associated with the severity of hospitalized respiratory infections.
  • Clinically, patients with viral respiratory infections can develop acute respiratory distress syndrome (ARDS), a life-threatening condition.
  • We look forward to conducting additional preclinical evaluation of bemcentinib's activity in severe respiratory infections to further bolster our understanding in this important area."

EQS-News: AATec Medical starts collaboration with the German Federal Agency for Disruptive Innovation SPRIND for alpha-1 antitrypsin

Retrieved on: 
Tuesday, February 6, 2024
Partnership, Alpha-1 antitrypsin deficiency, Research, Inflammation, Lung, Acute respiratory distress syndrome, COPD, AAT, Innovation, Viral, Asthma, Pharmaceutical industry

This project is a key step in the development of the innovative ATL-105 drug platform for the treatment of respiratory diseases.

Key Points: 
  • This project is a key step in the development of the innovative ATL-105 drug platform for the treatment of respiratory diseases.
  • As part of the collaboration with SPRIND, ATL-105 will be tested in various disease models for viral diseases of the respiratory tract.
  • Sigrid Koeth, Innovation Manager at SPRIND, emphasizes the importance of the project: "With SPRIND, we want to create disruptive innovations from Germany.
  • Dr. Rüdiger Jankowsky, co-founder and CEO of AATec, comments on the collaboration: "The partnership with SPRIND enables us to accelerate our research and development work and realize our innovation potential faster.

Chung-Ang University Study Looks at Cardiovascular Risks in COVID-19 Survivors

Retrieved on: 
Friday, January 12, 2024
Death, System, Mortality, BMC Medicine, Cardiac arrest, Patient, Research, Database, Pneumonia, Pneumonitis, Incidence, Hospital, Male, Fatigue, Survivor, Long-term care, Vaccination, Risk, Medicine, Chung-Ang University, COVID-19, White, Heart, Acute respiratory distress syndrome, Deep vein thrombosis, Infection, Cardiovascular disease, Pharmaceutical industry

Despite this, previous studies assessing cardiovascular outcomes in post-acute COVID-19 patients were limited by insufficiently adjusting for preexisting cardiovascular conditions among hospitalized individuals.

Key Points: 
  • Despite this, previous studies assessing cardiovascular outcomes in post-acute COVID-19 patients were limited by insufficiently adjusting for preexisting cardiovascular conditions among hospitalized individuals.
  • They aimed to explore the risk of cardiovascular outcomes among individuals who survived acute COVID-19 hospitalization without preexisting cardiovascular conditions.
  • Sensitivity analyses with preexisting cardiovascular disease and subgroup assessments confirmed these trends, emphasizing the impact of COVID-19 on cardiovascular outcomes.
  • While prior Western studies suggested elevated cardiovascular risks post-COVID-19, this research has revealed low risks in Korean patients following acute COVID-19 hospitalizations.

Ebenbuild to Receive Public Funding Under UBIC Consortium for Digital Lung Twin Project

Retrieved on: 
Tuesday, November 28, 2023
Trauma, Treatment, Acute respiratory distress syndrome, Death, Sepsis, Deep learning, German, Oxygen, COVID-19, Data science, Teaching hospital, Patient, Diagnosis, BMBF, Algorithm, Automation, ICU, Education, Medical device

In total, the consortium will receive up to Euro 1.8 million in funding from the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) for its project "Personalized Lung Twins for the Treatment of Acute Respiratory Distress Syndrome (UBIC)".

Key Points: 
  • In total, the consortium will receive up to Euro 1.8 million in funding from the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) for its project "Personalized Lung Twins for the Treatment of Acute Respiratory Distress Syndrome (UBIC)".
  • As part of the UBIC consortium, Ebenbuild will receive up to Euro 900.000 to develop novel AI and simulation technologies for modeling and researching heterogeneously damaged lungs and to improve digitally assisted decision-making in intensive care.
  • Ebenbuild develops personalized lung simulation models based on patient-specific data.
  • “We are delighted about the funding and our participation in the project,” said Dr. Kei Müller, CEO and co-founder of Ebenbuild.

SeaStar Medical Reports Third Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Tuesday, November 14, 2023
Chronic kidney disease, Neutrophil, Acute respiratory distress syndrome, STEC-HUS, Cardiorenal syndrome, Safety, Food, Hepatorenal syndrome, University, AKI, HDE, Risk, ICU, Clinical trial, Monocyte, Mortality, CBER, Sepsis, Patient, Nephrology, Insurance, Research, Letter, Dialysis, Approvable letter, FDA, G&A, Child, Standard of care, Acute kidney injury, Partnership, Nephron, Clinical study design, R, Hospital, SCD, Physician, CKRT, Karger Publishers, PMA, HIV disease progression rates, Pharmaceutical industry, Nursing, Dietary supplement, Cryptocurrency

DENVER, Nov. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and nine months ended September 30, 2023 and provides a business update.

Key Points: 
  • DENVER, Nov. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and nine months ended September 30, 2023 and provides a business update.
  • “Recent clinical and regulatory successes have significantly improved and strengthened our company’s prospects,” said Eric Schlorff, SeaStar Medical CEO.
  • SeaStar Medical expects regulatory approval for the SCD-ADULT in the first half of 2025 and commercial launch in the second half of 2025.
  • The Company issued two convertible notes each for $0.5 million in August 2023 and a third convertible note for $0.5 million in September 2023.

VERU ALERT: Bragar Eagel & Squire, P.C. is Investigating Veru Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, December 15, 2023
Class Action Lawsuit, Professional Services, Legal, NDA, Breast, Acute respiratory distress syndrome, Safety, Telephone, Complaint, Mortality, Patient, Fast track (FDA), Infection, FDA, Prostate cancer, Prostate Cancer Foundation, Jeanne Eagels, Aerospace, COVID-19, Standard of care, Trial of the century, Death, P.C, Form 10-Q, Fast Track, News, Cryptocurrency, Pharmaceutical industry, Tiberius Claudius Verus

Our investigation concerns whether the board of directors of Veru have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Veru have breached their fiduciary duties to the company.
  • Veru is primarily an oncology-based biopharmaceutical company that develops drugs for the management of breast and prostate cancers.
  • Veru had originally developed sabizabulin with the intention of using it as a treatment for prostate cancer.
  • At the time, there was no authorized or approved treatment for hospitalized patients with severe COVID-19 infections.

Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Thursday, November 9, 2023
EGFR, Research, HCC, NSCLC, AACR, Rheumatism, American Association for the Study of Liver Diseases, OMEGA, IND, International, Therapy, Hepatology, Flagship Pioneering, Liver regeneration, G&A, Investigational New Drug, Conference, Palatine Nos. 1–8, 21, Fibrosis, Dive (Belgian band), MYC, Hepatitis, R, Pharmacokinetics, Acute respiratory distress syndrome, Omega, Epigenomics, Lung, Tissue, Annual report, Messenger, LNP, Institutional review board, Inflammation, Lung cancer, Hepatocellular carcinoma, Cancer, Patient, Gene expression, AASLD, Management, Pharmaceutical industry, Vaccine, Dietary supplement

As of September 30, 2023, the Company had cash, cash equivalents and marketable securities totaling $89.3 million.

Key Points: 
  • As of September 30, 2023, the Company had cash, cash equivalents and marketable securities totaling $89.3 million.
  • Research and development (R&D) expenses for the third quarter of 2023 were $16.5 million, compared to $20.7 million for the third quarter of 2022.
  • General and administrative (G&A) expenses for the third quarter of 2023 were $7.9 million, compared to $5.2 million for the third quarter of 2022.
  • Net loss for the third quarter of 2023 was $22.2 million, compared to $25.8 million for the third quarter of 2022, driven predominantly by a decrease in R&D expenses.

EQS-News: AATec Medical and Beurer enter development collaboration for inhaled Alpha-1 Antitrypsin

Retrieved on: 
Tuesday, November 7, 2023
Plasma, Therapy, Inflammation, Research, Acute respiratory distress syndrome, Inhalation, Asthma, AAT, IP, Patient, Vaccine, Pharmaceutical industry, Beurer

The agreement foresees the development of next-generation inhaler devices for use with biopharmaceuticals using cutting-edge protein nebulization technology.

Key Points: 
  • The agreement foresees the development of next-generation inhaler devices for use with biopharmaceuticals using cutting-edge protein nebulization technology.
  • AATec and Beurer will join forces to provide innovative patient-centric products based on AATec’s expertise in biopharmaceutical development and Beurer’s inhalation technology.
  • Under the agreement, AATec will conduct preclinical and clinical development, regulatory approval, and commercialization.
  • Through the collaboration, AATec obtains access to advanced inhalation technology and manufacturing capacity, and Beurer expands the range of pharmaceutical applications of their products.

Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development

Retrieved on: 
Wednesday, October 11, 2023
Infection, ASPR, Inflammation, Injury, Development, Office of Inspector General, U.S. Department of Health and Human Services, Defence Research and Development Canada, University, Organization, Therapy, Administration, Organ transplantation, FDA, Biomedical Advanced Research and Development Authority, RVV, CSE, Acute respiratory distress syndrome, Disorder, DRDC, BARDA, Administration for Strategic Preparedness and Response, HHS, Research, Pharmaceutical industry, Bucillamine

TORONTO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, provides an update on the development of a next generation lyophilized formulation of Bucillamine.

Key Points: 
  • TORONTO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, provides an update on the development of a next generation lyophilized formulation of Bucillamine.
  • Under an agreement with the University of Waterloo, formulation development is ongoing and aims to be completed by the end of December 2023.
  • The Company expects to have its novel lyophilized formulation of Bucillamine ready for clinical evaluation in 2024.
  • The Company intends to explore the novel Bucillamine formulation as a potential treatment for public health medical emergencies including, pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks.

EQS-News: AATec Medical GmbH: AATec Medical Announces Creation of Scientific Advisory Board

Retrieved on: 
Tuesday, October 17, 2023
Health, GS, Georgetown University Medical Center, Viral, International Society, University Medical Center, Technical University of Munich, Leibniz-Institute of Virology, Institute of technology, Coronavirus Scientific Advisory Board, EMA, Asthma, Aerosol, Acute respiratory distress syndrome, Nature Communications, AAT, Research, ISAM, Pharmaceutical industry, Vaccine, Virology, Inam-ul-Haq (diplomat), Medicine

Leading scientific and clinical experts, Prof. Dr. Ulrike Protzer, Prof. Dr. Jan Münch, and Dr. Gerhard Scheuch, join the newly established Scientific Advisory Board

Key Points: 
  • Leading scientific and clinical experts, Prof. Dr. Ulrike Protzer, Prof. Dr. Jan Münch, and Dr. Gerhard Scheuch, join the newly established Scientific Advisory Board
    Munich, Germany – 10 October 2023 – AATec Medical GmbH (AATec), a biotech company developing a multi-product platform based on recombinant alpha-1 antitrypsin (AAT), today announced the creation of a Scientific Advisory Board.
  • Dr. Rüdiger Jankowsky, CEO commented: "We are honored to have such esteemed scientific experts joining AATec as advisors.
  • Our Scientific Advisory Board is composed of pioneers in the fields of respiratory diseases, viral infections, and aerosolized drugs.
  • The creation of the Scientific Advisory Board underscores AATec's commitment to unlocking the therapeutic potential of AAT, a human serine protease inhibitor with broad anti-inflammatory and antiviral effects to treat respiratory inflammatory diseases.